2023 World Conference on Lung Cancer (Posters)-EP11.02. Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS

EP11.02. Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS - PDF(Slides)

Back to course

Pdf Summary

This document is a poster presentation from the 2023 World Conference on Lung Cancer, discussing a subgroup analysis of Asian patients in the IPSOS trial comparing the efficacy and safety of atezolizumab versus single-agent chemotherapy in patients with non-small cell lung cancer (NSCLC) who were ineligible for platinum-doublet chemotherapy as a first-line treatment. <br /><br />The study found that atezolizumab demonstrated a consistent overall survival (OS) benefit over chemotherapy in the Asian subpopulation, which was consistent with the results observed in the intention-to-treat (ITT) population. Secondary efficacy endpoints, including objective response rate and progression-free survival, were also supportive of the results observed for OS in both the Asian subpopulation and ITT population. The adverse events (AEs) observed in the atezolizumab arm were generally similar to those seen in the global safety population for IPSOS and consistent with the expected safety profile of atezolizumab monotherapy.<br /><br />The baseline characteristics of the Asian subpopulation were generally similar to those of the ITT population, with a higher proportion of male patients in the Asian subpopulation and a lower proportion of patients with PD-L1 TC 1% tumors. The OS and PFS rates were numerically longer in the atezolizumab arm compared to the chemotherapy arm, and the confirmed objective response rate was higher in the atezolizumab arm. The proportion of patients who received subsequent anti-cancer therapies was also lower in the atezolizumab arm.<br /><br />In terms of safety, all-grade treatment-related AEs occurred at a lower rate in the atezolizumab arm compared to the chemotherapy arm, and the incidence of Grade 3/4 AEs was lower in the atezolizumab arm. However, serious AEs occurred at a higher rate in the atezolizumab arm, mainly driven by a greater incidence of pneumonia.<br /><br />Overall, this subgroup analysis suggests that the efficacy and safety of atezolizumab monotherapy compared to single-agent chemotherapy in patients ineligible for platinum-doublet chemotherapy is similar for Asian patients compared to the overall population.

Asset Subtitle

Baohui Han

Meta Tag

Speaker Baohui Han

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

2023 World Conference on Lung Cancer

subgroup analysis

Asian patients

IPSOS trial

efficacy

safety

atezolizumab

single-agent chemotherapy

non-small cell lung cancer

NSCLC